Key Insights

Highlights

Treatment Research

8 treatments under study, led by Sucralfate

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 4 (1)

Trial Status

Not Yet Recruiting2
Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT07679139Not ApplicableNot Yet RecruitingPrimary

Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study

NCT07540026Not ApplicableRecruitingPrimary

Endoscopic Application of Tranexamic Acid and Sucralfate in Gastrointestinal Tumor Bleeding: A Randomized Controlled Trial

NCT07257926Phase 4Not Yet RecruitingPrimary

Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial

NCT02594813RecruitingPrimary

Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents

Showing all 4 trials

Research Network

Common Treatments

  • Sucralfate2
  • Tranexamic Acid1
  • Tranexamic Acid And Sucralfate Powder Spray1
  • Standard Treatment1
  • Biopsy Cold Or Hot Snare Polypectomy Or Emr1

Active Sponsors

  • National Cheng-Kung University Hospital3
  • Showa Inan General Hospital1

Top Investigators

Activity Timeline